MEMPHIS, Tenn.--(BUSINESS WIRE)--Dec. 12, 2013--
GTx, Inc. (Nasdaq: GTXI) announced today a scientific presentation will
be made at the 2013 San Antonio Breast Cancer Symposium, December 10-14,
2013, in San Antonio, Texas, involving technology licensed from the
University of Tennessee Research Foundation and developed by the Company.
The presentation will take place on December 13, 2013 in Exhibit Hall, A
Poster Session 5: Tumor Cell and Molecular Biology:
Endocrine Therapy and Resistance
Receptor Modulators (SARMs): Enobosarm as Targeted Therapy for the
Treatment of Androgen Receptor-Positive Breast Cancer.
T. Dalton, Ramesh Narayanan and Mitchell S. Steiner of GTx, Inc. and Dr.
Beth Overmoyer, Director, Inflammatory Breast Cancer Program, Dana
Farber Cancer Institute and Assistant Professor of Medicine at the
Harvard Medical School
“We are delighted to be able to showcase important preclinical data
affirming our belief that enobosarm can become an important additional
hormonal treatment option for women with advanced breast cancer,” said
Dr. Mitchell Steiner, CEO and Vice-Chairman of GTx, Inc. “Medical
literature shows that 75 to 95% of women with estrogen positive breast
cancer also express androgen receptor positive. Enobosarm has the
potential to provide a nonsteroidal, tissue-selective novel targeted
approach to exploit the therapeutic benefits of androgen therapy in
breast cancer without the unwanted virilizing side effects or concerns
associated with non-tissue selective androgens, such as facial and body
hair, enlargement of the voice box, acne and edema.”
GTx is currently conducting a proof of concept, Phase 2, open-label
clinical study to evaluate enobosarm (GTx-024), a selective androgen
receptor modulator (SARM), for the potential treatment of metastatic
breast cancer. The company expects to complete enrollment of the
approximately 20 patients for this study in December, 2013 and receive
data from the study late in the second quarter of 2014.
About Breast Cancer And Receptor Status
Breast cancer is the most commonly diagnosed cancer in women, and the
second leading cause of cancer deaths in women in the United States.
Each year, over 200,000 new cases of invasive breast cancer will be
diagnosed in the U.S., and approximately 39,000 women will die from the
disease. Clinical assessment of breast cancer includes routine
characterization of a patient’s receptor status, including the presence
or absence of estrogen receptor (ER), progesterone receptor, and human
epidermal growth factor receptor 2 (HER2) in the tumor tissue. Receptor
status is used to assess the potential for developing metastatic
disease, as well as guiding treatment decisions. Hormonal manipulation
with selective estrogen receptor modulators or aromatase inhibitors is
the standard treatment given to patients with tumors that are ER
positive. It is expected that a majority (70-95%) of women with ER
positive breast cancer will also express androgen receptor (AR) in their
primary tumor samples. High percentages (72-84%) of metastatic breast
cancer lesions have also been found to be AR positive. In preclinical
and clinical studies, androgens have been shown to suppress breast
cancer growth. In addition, prior studies have shown that women with
metastatic breast cancer who have been previously treated with tamoxifen
and progress have responded to nonselective androgens like
fluoxymesterone, medroxyprogesterone and danazol, with overall response
rates ranging from 20 to 60%. Although these nonselective androgens have
been used to treat breast cancer, the unwanted virilizing side effects,
including facial and body hair, enlargement of voice box, acne, and
edema, have limited their widespread clinical use.
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical
company dedicated to the discovery, development, and commercialization
of small molecules for the treatment of cancer, cancer supportive care,
including prevention and treatment of cancer-related muscle wasting, and
other serious medical conditions.
Source: GTx, Inc.
Denise Powell, 510-703-9491
Marc Hanover, 901-507-6915
President and Chief Operating